Clinical Trials Logo
  1. Home
  2. Lymphoblastic Lymphoma
  3. NCT03571997
  4. Details
NCT03571997 Clinical Trial

Study of Prognostic Factors in Adult Lymphoblastic Lymphoma

Lymphoblastic Lymphoma Clinical Trial

Official title:
FPLLA-PETHEMA-001: Study of Prognostic Factors in Adult Lymphoblastic Lymphoma

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT03571997
Other study ID # FPLLA-PETHEMA-001
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 15, 2018
Est. completion date December 30, 2022

Study information
Verified date January 2022
Source PETHEMA Foundation
Contact Miguel Sagüés Serrano, Dr
Phone 972 225 158
Email msagues@iconcologia.net
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Retrospective observational study with systematic collection of data on filiation (age at diagnosis and sex), clinical data (IPI, ECOG, early response to chemotherapy, overall response to chemotherapy), biological (strain B or T, infiltration of the nervous system central [CNS], bone marrow [MO], lactate dehydrogenase (LDH) level at the time of diagnosis, as well as genetic patients included in the study, as well as the PETHEMA protocol used in the treatment of same patients The study will review the PETHEMA protocols from 2003 to the present

Description:

Retrospective observational study with systematic collection of data on filiation (age at diagnosis and sex), clinical data (IPI, ECOG, early response to chemotherapy, overall response to chemotherapy), biological (strain B or T, infiltration of the nervous system central [CNS], bone marrow [MO], lactate dehydrogenase (LDH) level at the time of diagnosis, as well as genetic patients included in the study, as well as the PETHEMA protocol used in the treatment of same patients The study will review the PETHEMA protocols from 2003 to the present. Analysis of the main clinical-biological variables as independent risk factors in adult patients (> 15 years) diagnosed with ALL

Recruitment information / eligibility
Status Recruiting
Enrollment 30
Est. completion date December 30, 2022
Est. primary completion date December 30, 2022
Accepts healthy volunteers No
Gender All
Age group 15 Years and older
Eligibility Inclusion Criteria: Patients >15 years old diagnosed with ALL and treated with the PETHEMA protocols for ALL Exclusion Criteria: None

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
Spain Hospital General de Alicante Alicante
Spain H. de la Santa Creu I Sant Pau Barcelona
Spain H. Vall d'Hebron, Barcelona Barcelona
Spain H.Universitari Germans Trias I Pujol de Badalona Barcelona
Spain Hospital Clínic de Barcelona Barcelona
Spain Hospital de Basurto Basurto
Spain ICO-Duran i Reynals Bellvitge
Spain Hospital Donostia Donostia
Spain H. Univ. de Girona Dr. Josep Trueta (ICO) Girona
Spain Hospital Arnau de Vilanova (Lleida) Lleida
Spain Hospital Lucus Augusti Lugo
Spain H. Gregorio Marañón Madrid
Spain Hospital San Pedro de Alcántara. Málaga
Spain Hospital General Universitario Morales Messeguer Murcia
Spain Hospital Central de Asturias Oviedo Asturias
Spain Hospital Son Espases Palma De Mallorca
Spain Hospital Son Llatzer Palma de Mallorca
Spain Complejo Hospitalario de Navarra Pamplona
Spain Parc Taulí Sabadell
Spain H. Univ. de Salamanca Salamanca
Spain C. H. U. de Santiago Santiago de Compostela
Spain Complejo Hosp. Regional Virgen del Rocío Sevilla
Spain Hospital del Valme Sevilla
Spain H. Joan XXIII Tarragona
Spain Hospital Mútua de Terrassa Terrassa Barcelona
Spain Hoapital La Fe Valencia
Spain Hospital Arnau de Vilanova (Valencia) Valencia
Spain Hospital Universitari Clínic València Valencia

Sponsors (1)
Lead Sponsor Collaborator
PETHEMA Foundation

Country where clinical trial is conducted

Spain, 

Outcome
Type Measure Description Time frame Safety issue
Primary Description pronostic factors Study of the main clinical-biological variables as independent risk factors in adult patients (> 15 years) diagnosed with ALL 1 year
Secondary overall survival To study if there has been an increase in overall survival (OS), in patients diagnosed with ALL in the different PETHEMA protocols 1 year
Secondary Progression free survival To study if there has been an increase in progression-free survival (PFS) in patients diagnosed with ALL in the different PETHEMA protocols 1 year
See also
  Status Clinical Trial Phase
Completed NCT04666025 - SARS-CoV-2 Donor-Recipient Immunity Transfer
Terminated NCT02257684 - A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) /Lymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargase (Oncaspar) Phase 2
Completed NCT01943682 - Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma Phase 1
Completed NCT00866749 - Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma Phase 2
Recruiting NCT02938741 - ATG Based Conditioning Regimen in HLA Related HSCT for Aggressive T-cell Tumors Phase 4
Completed NCT02912676 - Thiopurine EnhAnced Maintenance Therapy Phase 1/Phase 2
Terminated NCT01910428 - L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) for Treatment of Adult Patients With ALL or LBL Phase 1
Active, not recruiting NCT02506933 - Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant Phase 2
Active, not recruiting NCT04060277 - Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation Phase 2
Completed NCT03181126 - A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma Phase 1
Completed NCT01643408 - A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy Phase 2
Active, not recruiting NCT00719888 - Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease Phase 2
Terminated NCT02419469 - Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Phase 2
Recruiting NCT05476770 - Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies Phase 1
Recruiting NCT05885464 - A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) Phase 1/Phase 2
Completed NCT01451515 - NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma Phase 2
Terminated NCT01100658 - Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors N/A
Recruiting NCT05794880 - MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing N/A
Completed NCT02661035 - Allo HSCT Using RIC for Hematological Diseases Phase 2
Recruiting NCT01790152 - Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment